An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
IMPLANET Announces the First Surgical Operations in the United States with the ORIGIN Cervical Plate
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
IMPLANET announces the successful first surgeries in the United States using its ORIGIN cervical plate, a product of its merger with Orthopaedic & Spine Development (OSD). This expansion into the U.S. market, valued at $1.35 billion annually, follows FDA clearance and CE marking for the ORIGIN range. CEO Ludovic Lastennet highlights the potential for rapid growth through their enhanced product offerings, aimed at capitalizing on synergies with OSD’s distribution network. Over 7,000 plates have been sold globally since launch.
Positive
Successful first surgeries in the U.S. using ORIGIN cervical plates.
Expansion into a U.S. market valued at $1.35 billion with over 368,000 surgeries.
Over 7,000 ORIGIN plates sold globally, indicating strong market acceptance.
Synergies from the merger with OSD enhancing the product portfolio and distribution.
Negative
None.
First synergies with OSD products in the United States
Strengthening of Implanet’s presence in the U.S. Spine market
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans) (Paris:ALIMP), a medical technology company specialized in vertebral implants, today announces the first surgeries in the United Stations with the ORIGIN cervical plate, from OSD’s Cervical range.
Phillip Esce MD, of Carolina Orthopaedic & Neurosurgical Associates, said: “I regularly use cervical plates in my surgical practice. This new implant was easy and fast to use during the first cases, and the post-operative clinical outcome is highly satisfactory. We will now monitor these patients to confirm the results over the longer term”.
Ludovic Lastennet, CEO of IMPLANET, added: “These first implantations are the consequence of the synergies resulting from our merger with OSD, reflecting the advantages of expanding our range of implants for spine surgery. We intend to build on this initial success and intensify our commercial approach, notably in the United States. Our network of agents will now be able to present surgeons with an enhanced range that includes the ORIGIN cervical plate, which has CE marking and FDA clearance. This first step should rapidly lead us to establish our offer on the American market in the field of cervical spine surgery, estimated at $1.35 billion with over 368,000 surgeries1".
Following the acquisition of Orthopaedic & Spine Development (OSD) and thanks to its Boston-based commercial subsidiary, Implanet was able to initiate the commercial promotion of the ORIGIN range of anterior cervical plates in the United States in late 2021. These cervical plates are now at the heart of Implanet’s product portfolio and have allowed the Company to sign numerous commercial agreements, such as the partnership signed with ulrich medical® in 2021.
ORIGIN range sales have been constantly growing since it was first marketed, with more than 7,000 plates sold worldwide to date. Having received CE marking in 2009, the ORIGIN cervical plate range was granted 510(k) regulatory clearance from the FDA (Food and Drug Administration) in the United States in 2020.
These surgical operations are the first tangible results of the synergies generated with OSD. For the last 6 months, Implanet has been capitalizing on both entities’ distribution networks and customers to increase its volume of business. The recent signing of a partnership with ulrich medical® for the distribution of JAZZ® implants and ORIGIN cervical plates in Germany also represents a growth factor for business, as do the synergies products by combining JAZZ Cap and JAZZ PF with OSD’s SAXXO pedicle screw range.
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. IMPLANET employs 29 staff and recorded a consolidated revenue of €6.1 million in 2021. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris. For further information, please visit www.implanet.com.
The Company would like to remind readers that the table for monitoring the equity line (OCA, BSA) and the number of shares outstanding is available on its website: http://www.implanet-invest.com/suivi-des-actions-80
NewCap
Media Relations
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
implanet@newcap.eu
Source: IMPLANET
FAQ
What is the significance of Implanet's first surgeries in the U.S. for IMPZY?
The first surgeries using Implanet's ORIGIN cervical plate in the U.S. signify a critical expansion into a lucrative market valued at $1.35 billion, potentially driving revenue growth for IMPZY.
How many ORIGIN cervical plates have been sold globally?
Implanet has sold over 7,000 ORIGIN cervical plates worldwide since their launch.
What are the expected benefits from Implanet's merger with OSD?
The merger with OSD is expected to generate synergies that enhance product offerings and expand distribution networks, particularly in the U.S. market.
What is the market size for cervical spine surgery that Implanet is targeting?
The cervical spine surgery market that Implanet is targeting is estimated to be worth $1.35 billion.
What regulatory approvals does the ORIGIN cervical plate have?
The ORIGIN cervical plate has received CE marking and 510(k) regulatory clearance from the FDA for use in the United States.
